A Leary
Overview
Explore the profile of A Leary including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
681
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu-Vuillard A, Guerin-Charbonnel C, Bocquet F, Cheeseman S, Kubelac P, Zenatri M, et al.
ESMO Open
. 2024 Sep;
9(9):103694.
PMID: 39232440
Background: Poly(ADP-ribose) polymerase inhibitors (PARPis) improved advanced ovarian cancer treatment. Most patients progress during or following PARPi exposure, however, with concerns about sensitivity of subsequent chemotherapy. Patients And Methods: In...
2.
Blanc-Durand F, Pautier P, Michels J, Leary A
ESMO Open
. 2024 Mar;
9(3):102936.
PMID: 38492450
No abstract available.
3.
Ledermann J, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al.
Ann Oncol
. 2024 Feb;
35(3):248-266.
PMID: 38307807
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June...
4.
Gonzalez-Martin A, Harter P, Leary A, Lorusso D, Miller R, Pothuri B, et al.
Ann Oncol
. 2023 Aug;
34(10):833-848.
PMID: 37597580
No abstract available.
5.
Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonzalez-Martin A, Marth C, et al.
Ann Oncol
. 2023 May;
34(8):681-692.
PMID: 37211045
Background: In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer patients in clinical response after first-line platinum-based...
6.
Nassif E, Blay J, Massard C, Dufresne A, Brahmi M, Cassier P, et al.
ESMO Open
. 2022 Mar;
7(2):100425.
PMID: 35255445
Background: The prognosis of patients with advanced soft-tissue sarcomas (STS) remains dismal, and systemic therapeutic options are limited. Early phase trials are becoming increasingly safe and effective. This study aimed...
7.
Morice P, Maulard A, Scherier S, Sanson C, Zarokian J, Zaccarini F, et al.
Gynecol Oncol
. 2022 Mar;
165(1):169-183.
PMID: 35241291
Background: Several techniques can be proposed as fertility sparing surgery in young patients treated for cervical cancer but uncertaincies remain concerning their outcomes. Analysis of oncological issues is then the...
8.
Chargari C, Arbyn M, Leary A, Abu-Rustum N, Basu P, Bray F, et al.
Gynecol Oncol
. 2021 Oct;
164(1):231-241.
PMID: 34716024
Human papillomaviruses (HPV)-related gynecological cancers are a major health care issue, and a leading cause of cancer death in low- and middle-income countries (LMIC). In 2020, the World Health Organization...
9.
Breban-Kehl M, Zaccarini F, Sanson C, Maulard A, Scherier S, Genestie C, et al.
Gynecol Obstet Fertil Senol
. 2021 Sep;
50(1):62-68.
PMID: 34487915
Objectives: The strategy of fertility preservation (FP) in cervical cancer has been challenged for several years and a therapeutic de-escalation seems to be necessary. In this context, we evaluated the...
10.
Martin J, Khalife-Hachem S, Grinda T, Kfoury M, Garciaz S, Pasquier F, et al.
Ann Oncol
. 2021 Jun;
32(8):1046-1048.
PMID: 34107346
No abstract available.